These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sequence variation in PPARG may underlie differential response to troglitazone. Wolford JK; Yeatts KA; Dhanjal SK; Black MH; Xiang AH; Buchanan TA; Watanabe RM Diabetes; 2005 Nov; 54(11):3319-25. PubMed ID: 16249460 [TBL] [Abstract][Full Text] [Related]
7. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Pinelli NR; Cha R; Brown MB; Jaber LA Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626 [TBL] [Abstract][Full Text] [Related]
8. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Fonseca VA Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Buckingham RE; Hanna A Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890 [TBL] [Abstract][Full Text] [Related]
11. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Yau H; Rivera K; Lomonaco R; Cusi K Curr Diab Rep; 2013 Jun; 13(3):329-41. PubMed ID: 23625197 [TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Toprani A; Fonseca V Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120 [TBL] [Abstract][Full Text] [Related]
13. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus. Kudzma DJ Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410 [TBL] [Abstract][Full Text] [Related]
14. Pioglitazone: side effect and safety profile. Shah P; Mudaliar S Expert Opin Drug Saf; 2010 Mar; 9(2):347-54. PubMed ID: 20175701 [TBL] [Abstract][Full Text] [Related]
15. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. Wang M; Tafuri S J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906 [TBL] [Abstract][Full Text] [Related]
16. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. Lin KD; Chang YH; Wang CL; Yang YH; Hsiao PJ; Li TH; Shin SJ Transl Res; 2008 Jun; 151(6):309-14. PubMed ID: 18514142 [TBL] [Abstract][Full Text] [Related]
17. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Phielix E; Szendroedi J; Roden M Trends Pharmacol Sci; 2011 Oct; 32(10):607-16. PubMed ID: 21824668 [TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Blaschke F; Caglayan E; Hsueh WA Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586 [TBL] [Abstract][Full Text] [Related]
19. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Durbin RJ Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752 [TBL] [Abstract][Full Text] [Related]
20. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]